Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid

Neurobiology of Aging

Volumn 26, Issue 2, 2005, Pages 207-227

  Zhang, Jing ^a   Goodlett, David R ^b   Peskind, Elaine R ^c   Quinn, Joseph F ^d   Zhou, Yong ^a   Wang, Qin ^a   Pan, Catherine ^a   Yi, Eugene ^b   Eng, Jimmy ^b   Aebersold, Ruedi H ^b   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c Education   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aging; Cerebrospinal fluid; ICAT; Proteins; Proteomics

Indexed keywords

BIOLOGICAL MARKER; ISOTOPE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETIC CODE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; VALIDATION PROCESS; WESTERN BLOTTING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BLOTTING, WESTERN; CEREBROSPINAL FLUID PROTEINS; CHROMATOGRAPHY, LIQUID; DATABASES, PROTEIN; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 10044279102     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2004.03.012     Document Type: Article

References (43)

1. Aebersold R., Goodlett D.R. Mass spectrometry in proteomics. Chem. Rev. 101:2001;269-295
2. Baker S.G. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J. Natl Cancer Inst. 95:2003;511-515
3. Blennow K., Davidsson P., Wallin A., Ekman R. Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? Dementia. 6:1995;306-311
4. Blennow K., Fredman P., Wallin A., Gottfries C.G., Karlsson I., Langstrom G., et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur. Neurol. 33:1993;129-133
5. Blennow K., Fredman P., Wallin A., Gottfries C.G., Langstrom G., Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur. Neurol. 33:1993;126-128
6. Blennow K., Fredman P., Wallin A., Gottfries C.G., Skoog I., Wikkelso C., et al. Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production. Eur. Neurol. 33:1993;134-142
7. Cheng F.C., Kuo J.S., Chia L.G., Dryhurst G. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural. Transm. 103:1996;433-446
8. Choe L.H., Green A., Knight R.S., Thompson E.J., Lee K.H. Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis. 23:2002;2242-2246
9. Cohen N.A., Kaufmann W.E., Worley P.F., Rupp F. Expression of agrin in the developing and adult rat brain. Neuroscience. 76:1997;581-596
10. Davidsson P., Folkesson S., Christiansson M., Lindbjer M., Dellheden B., Blennow K., et al. Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 16:2002;2083-2088
11. Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport. 13:2002;611-615
12. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64:2001;575-611
13. Flicker C., Ferris S.H., Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 41:1991;1006-1009
14. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198
15. Forde C.E., McCutchen-Maloney S.L. Characterization of transcription factors by mass spectrometry and the role of SELDI-MS. Mass Spectrom Rev. 21:2002;419-439
16. Goodlett D.R., Keller A., Watts J.D., Newitt R., Yi E.C., Purvine S., et al. Differential stable isotope labeling of peptides for quantitation and de novo sequence derivation. Rapid Commun. Mass Spectrom. 15:2001;1214-1221
17. Goodlett D.R., Yi E.C. Proteomics without polyacrylamide: qualitative and quantitative uses of tandem mass spectrometry in proteome analysis. Funct. Integr. Genomics. 2:2002;138-153
18. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17:1999;994-999
19. Harrington M.G., Merril C.R. Cerebrospinal fluid protein analysis in diseases of the nervous system. J. Chromatogr. 429:1988;345-358
20. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74:2002;5383-5892
21. Keller A., Purvine S., Nesvizhskii A.I., Stolyar S., Goodlett D.R., Kolker E. Experimental protein mixture for validating tandem mass spectral analysis. Omics. 6:2002;207-212
22. Li X.J., Zhang H., Ranish J.A., Aebersold R. Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. Anal. Biochem. 75:2003;6648-6657
23. Li Z., Massengill J.L., O'Dowd D.K., Smith M.A. Agrin gene expression in mouse somatosensory cortical neurons during development in vivo and in cell culture. Neuroscience. 79:1997;191-201
24. Link A.J., Eng J., Schieltz D.M., Carmack E., Mize G.J., Morris D.R., et al. Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17:1999;676-682
25. Loeffler D.A., Brickman C.M., Juneau P.L., Perry M.F., Pomara N., Lewitt P.A. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease. Neurobiol. Aging. 18:1997;555-557
26. Mattis S, Coblentz J. In: Belleck L, Karasu T, editors. Mental status examination for organic mental syndrome in the elderly patient. Geriatric psychiatry: a handbook for psychiatrists and primary care physicians. New York: Grune and Stratton; 1976. p. 77-121.
27. McIntosh M.W., Pepe M.S. Combining several screening tests: optimality of the risk score. Biometrics. 58:2002;657-664
28. Milhorat TH, Cerebrospinal fluid as a reflection of internal milieu of brain. In: JH Wood, editor. Neurobiology of cerebrospinal fluid. New York: Plenum Press; 1983.
29. Montine T.J., Beal M.F., Cudkowicz M.E., O'Donnell H., Margolin R.A., McFarland L., et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology. 52:1999;562-565
30. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 9:1997;173-176. [discussion 177-8]
31. Osman I., Gaillard O., Meillet D., Bordas-Fonfrede M., Gervais A., Schuller E., et al. A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases. Eur. J. Clin. Chem. Clin. Biochem. 33:1995;53-58
32. Pepe M.S. An interpretation for the ROC curve and inference using GLM procedures. Biometrics. 56:2000;352-359
33. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577
34. Pratico D., V M.Y.L., Trojanowski J.Q., Rokach J., Fitzgerald G.A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12:1998;1777-1783
35. Reitan R. Validity of the trail-making test as an indication of organic brain damage. Percept. Mot. Skills. 8:1958;271-276
36. Sickmann A., Dormeyer W., Wortelkamp S., Woitalla D., Kuhn W., Meyer H.E. Towards a high resolution separation of human cerebrospinal fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 771:2002;167-196
37. Verbeek M.M., De Jong D., Kremer H.P. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann. Clin. Biochem. 40:2003;25-40
38. Wardlaw J.M., Sandercock P.A., Dennis M.S., Starr J., Farkas E., Luiten P.G. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Cerebral microvascular pathology in aging and Alzheimer's disease. Stroke. 34:2003;806-812
39. Washburn M.P., Wolters D., Yates J.R. III Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19:2001;242-247
40. Wood JH, Physiology, pharmacology, and dynamics of cerebrospinal fluid. In: Wood JH, editor. Neurobiology of cerebrospinal fluid, vol. 1. New York: Plenum; 1980.
41. Yi E.C., Marelli M., Lee H., Purvine S.O., Aebersold R., Aitchison J.D., et al. Approaching complete peroxisome characterization by gas-phase fractionation. Electrophoresis. 23:2002;3205-3326. order
42. Yuan X., Russell T., Wood G., Desiderio D.M. Analysis of the human lumbar cerebrospinal fluid proteome. Electrophoresis. 23:2002;1185-1196
43. Zhang J., Fitsanakis V., Gu G., Jing D., Ao M., Amarnath V., et al. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J. Neurochem. 84:2003;1-11